Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer (Q34616549)

3 August 2017

Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer (English)

1 reference

3 August 2017

1 reference

1 reference

1 reference

17

David M Gershenson

1 reference

3 August 2017

19

Anil K Sood

1 reference

3 August 2017

William M Merritt

1

1 reference

3 August 2017

Aparna A Kamat

2

1 reference

3 August 2017

Jee-Young Hwang

3

1 reference

3 August 2017

Justin Bottsford-Miller

4

1 reference

3 August 2017

Chunhua Lu

5

1 reference

3 August 2017

Yvonne G Lin

6

1 reference

3 August 2017

Donna Coffey

7

1 reference

3 August 2017

Whitney A Spannuth

8

1 reference

3 August 2017

Elizabeth Nugent

9

1 reference

3 August 2017

Liz Y Han

10

1 reference

3 August 2017

Charles N Landen

11

1 reference

3 August 2017

Alpa M Nick

12

1 reference

3 August 2017

Rebecca L Stone

13

1 reference

3 August 2017

Karen Coffman

14

1 reference

3 August 2017

Elizabeth Bruckheimer

15

1 reference

3 August 2017

Russell R Broaddus

16

1 reference

3 August 2017

Robert L Coleman

18

1 reference

3 August 2017

15 December 2010

1 reference

Cancer Biology and Therapy

3 August 2017

1 reference

3 August 2017

10

1 reference

3 August 2017

12

1 reference

3 August 2017

1306-1314

1 reference

3 August 2017

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

EphA2 overexpression is associated with angiogenesis in ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Eph receptor signalling casts a wide net on cell behaviour

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

EphA2 expression is associated with aggressive features in ovarian carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Docetaxel: an alternative taxane in ovarian cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Differential regulation of EphA2 in normal and malignant cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

The ephrins and Eph receptors in neural development

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Expression of two novel eph-related receptor protein tyrosine kinases in mammary gland development and carcinogenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

A novel putative tyrosine kinase receptor encoded by the eph gene

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.

7 July 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.10.12.13582

Overexpression of the EphA2 tyrosine kinase in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.10.12.13582

Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.10.12.13582

Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4161%2FCBT.10.12.13582

Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

EphA2 overexpression causes tumorigenesis of mammary epithelial cells.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3047089

26 October 2018

Endometrial carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20948320

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4161/CBT.10.12.13582

1 reference

3 August 2017

1 reference

3 August 2017

1 reference